| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|---|---|---|---|---|---|---|---|---|---|
Net revenues | ||||||||||
6,138 | 44,789 | 143,161 | 294,547 | 659,690 | 624,608 | 558,588 | 484,732 | 437,645 | 404,241 | 348,157 |
Net product revenues | ||||||||||
- | - | - | 240,688 | 659,690 | 624,608 | - | - | - | - | - |
Royalty revenues | ||||||||||
- | - | - | 53,859 | 0 | 0 | - | - | - | - | - |
Operating expenses: | ||||||||||
Cost of revenues | ||||||||||
7,255 | 47,193 | 60,653 | 103,986 | 233,330 | 216,636 | 177,339 | 156,866 | 129,299 | 118,148 | 88,355 |
Asset impairment charges | ||||||||||
5,073 | 392,097 | 0 | 0 | - | - | - | - | - | - | - |
Research and development | ||||||||||
133,007 | 138,370 | 92,107 | 90,388 | 139,512 | 138,260 | 126,423 | 110,180 | 85,241 | 117,610 | 105,720 |
Selling, general and administrative | ||||||||||
52,214 | 132,225 | 212,482 | 285,300 | 314,954 | 247,823 | 171,753 | 159,617 | 158,690 | 193,832 | 164,903 |
Total operating expenses | ||||||||||
197,549 | 709,885 | 365,242 | 479,674 | 687,796 | 602,719 | 475,515 | 426,663 | 373,230 | 429,590 | 358,978 |
Loss from operations | ||||||||||
-191,411 | -665,096 | -222,081 | -185,127 | -28,106 | 21,889 | 83,073 | 58,069 | 64,415 | -25,349 | -10,821 |
Legal settlement | ||||||||||
- | - | - | 5,000 | 25,736 | 0 | 0 | 17,984 | 0 | 0 | - |
Co-promotion and license income | ||||||||||
1,019 | 7,549 | 3,854 | 10,132 | 24,236 | 17,383 | - | - | - | - | - |
Loss on short-term investment | ||||||||||
-51,881 | 0 | 0 | 19,773 | 0 | 0 | - | - | - | - | - |
Gain on remeasurement of equity investment | ||||||||||
- | - | - | 22,597 | 0 | 0 | - | - | - | - | - |
Gain on sale of business | ||||||||||
0 | 0 | 288,301 | 0 | 0 | - | - | - | - | - | - |
Co-promotion and profit share income | ||||||||||
- | - | - | - | - | - | 10,000 | 0 | 0 | - | - |
Loss in equity investment | ||||||||||
- | - | - | - | -1,711 | 0 | 0 | - | - | - | - |
Loss on extinguishment of debt | ||||||||||
0 | 0 | -5,380 | 0 | 0 | - | - | - | - | - | - |
Interest expense | ||||||||||
49,411 | 48,564 | 44,463 | 37,092 | 15,701 | 15,531 | 8,005 | 0 | 0 | - | - |
Investment impairment | ||||||||||
- | - | - | - | 7,500 | 0 | 0 | - | - | - | - |
Other income | ||||||||||
5,580 | 1,840 | 346 | 188 | 918 | 1,420 | 1,140 | 1,790 | -267 | -2,818 | 5,235 |
Loss from continuing operations before income taxes | ||||||||||
-286,104 | -704,271 | 20,577 | -164,529 | -2,128 | 25,161 | 86,208 | 77,843 | 64,148 | -28,167 | -5,586 |
(Provision for) benefit from income taxes | ||||||||||
-50,888 | -96,576 | 67 | -29,733 | -2,309 | 2,273 | 35,038 | -50,034 | -40,487 | 48,062 | 2,918 |
Loss from continuing operations | ||||||||||
-235,216 | -607,695 | 20,564 | -134,806 | 319 | - | - | - | - | - | - |
(Loss) income from discontinued operations, net of tax | ||||||||||
112,060 | -100,678 | -139,682 | -217,950 | -32,529 | -7,628 | - | - | - | - | - |
Net loss attributable to non-controlling interest | ||||||||||
0 | 0 | -54 | 10 | -138 | -252 | -84 | 0 | 0 | - | - |
Net Income (Loss) Attributable to Parent | ||||||||||
-123,156 | -708,373 | -119,118 | -352,756 | -32,210 | 15,512 | 51,170 | 127,877 | 104,635 | -76,229 | -8,504 |
(Loss) income from continuing operations | ||||||||||
-235,216 | -607,695 | 20,510 | -134,796 | 181 | 22,888 | - | - | - | - | - |
Loss from discontinued operations, net of tax | ||||||||||
- | - | - | -217,950 | -32,529 | - | - | - | - | - | - |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||||||
-123,156 | -708,373 | -119,172 | -352,746 | -32,348 | 15,260 | 51,254 | 127,877 | 104,635 | - | - |
Net loss attributable to The Medicines Company | ||||||||||
-123,156 | -708,373 | -119,118 | -352,756 | -32,210 | 15,512 | 51,170 | 127,877 | 104,635 | -76,229 | -8,504 |
Basic loss per common share: | ||||||||||
Loss from continuing operations (USD per share) | ||||||||||
-3.20 | -8.40 | 0.29 | -2.02 | 0.00 | 0.40 | - | - | - | - | - |
(Loss) earnings from discontinued operations (USD per share) | ||||||||||
1.52 | -1.39 | -2.00 | -3.26 | -0.50 | -0.13 | - | - | - | - | - |
Basic loss per share (USD per share) | ||||||||||
-1.68 | -9.79 | -1.71 | -5.28 | -0.50 | 0.27 | 0.96 | 2.39 | 1.98 | -1.46 | -0.16 |
Diluted loss per common share: | ||||||||||
Loss from continuing operations (USD per share) | ||||||||||
-3.20 | -8.40 | 0.28 | -2.02 | 0.00 | 0.37 | - | - | - | - | - |
(Loss) earnings from discontinued operations (USD per share) | ||||||||||
1.52 | -1.39 | -1.91 | -3.26 | -0.49 | -0.12 | - | - | - | - | - |
Diluted loss per share (USD per share) | ||||||||||
-1.68 | -9.79 | -1.63 | -5.28 | -0.49 | 0.25 | 0.93 | 2.35 | 1.97 | -1.46 | -0.16 |
Weighted average number of common shares outstanding: | ||||||||||
Basic (shares) | ||||||||||
73,571 | 72,356 | 69,909 | 66,809 | 64,473 | 58,096 | 53,545 | 53,496 | 52,842 | 52,269 | 51,904 |
Diluted (shares) | ||||||||||
73,571 | 72,356 | 73,022 | 66,809 | 66,668 | 62,652 | 55,346 | 54,407 | 53,184 | 52,269 | 51,904 |